Tim trio 3t mr scanner

A Siemens 3T Tim Trio MR scanner system with a standard birdcage head coil for signal transmission/reception (MAGNETOM, Siemens, Healthcare, Germany) was used to acquire all images. BOLD-contrast-weighted echo-planar images (EPI) were registered as functional scans consisting of 40 interleaved, axial slices of 2.2 mm thickness (with a gap, of 30%) that partially covered the brain from about −57.2 below to about 57.2 mm above the P-A plane. The in-plane resolution was 3 × 3 mm, with the following parameters: FOV = 210 mm, matrix = 70 × 70; echo time (TE) = 23 ms; TR = 3 s with no time gap; flip angle = 90°. The first five volumes were discarded to allow for T1 equilibration effects. Additionally, an MPRAGE T1-weighted structural image (1 × 1 × 1 mm resolution) was acquired with the following parameters: echo time (TE) = 2.52 ms, repetition time (TR) = 2250 ms, flip angle = 90°, and field of view (FOV) = 256 mm. This yielded 176 contiguous 1 mm thick slices in a sagittal orientation.

Patients with recurrent GBM to be treated with the standard dose of bevacizumab 10 mg/kg every 2 weeks were eligible to participate in this study. Patients could receive concomitant chemotherapy with lomustine every 6 weeks as well. Both bevacizumab and lomustine are approved therapies for GBM and the combination has been shown to improve progression-free survival but not overall survival.^{14 (link)} Measurable disease, defined by at least one lesion that could be measured in at least one dimension (longest diameter to be recorded) as > 10 mm, was required. Patients with lower grade tumors that had progressed to GBM were eligible and all patients had to be >12 weeks from the completion of radiation. All patients signed informed consent, and this trial was approved by the Dana-Farber Harvard Cancer Center IRB (NCT02076152) in accordance with U.S. Common Rule. Patients underwent a baseline simultaneous PET-MRI scan (using the BrainPET prototype integrated with the 3T TimTrio MR scanner, Siemens Healthineers) prior to starting bevacizumab and prior to the second and third doses of bevacizumab (week 2 and week 4 of treatment). Additionally, MRI-only scans were performed 1 day after the first bevacizumab infusion, and then every 6 weeks in the lomustine cohort or every 8 weeks in the bevacizumab monotherapy cohort (Supplementary Figure 1).

A Siemens 3T Tim Trio MR scanner system with a standard birdcage head coil for signal transmission/reception (MAGNETOM, Siemens, Healthcare, Germany) was used to acquire all images. BOLD-contrast-weighted echo-planar images (EPI) for functional scans consisted of 40, interleaved, axial slices of 2.2 mm thickness (with gap, 30%) that partially covered the brain from about -57.2 below to about 57.2 mm above the P-A plane. In-plane resolution was 3 x 3 mm, with the following parameters: FOV = 210 mm, matrix = 70 x 70; echo time (TE) = 23 ms; TR = 3 s with no time gap; flip angle = 90°. The first five volumes of each run were discarded to allow for T1 equilibration effects. Subsequently, a MPRAGE T1-weighted structural image (1 x 1 x 1 mm resolution) was acquired for coregistration and display of the functional data, with the following parameters: echo time (TE) = 2.52 ms, repetition time (TR) = 2250 ms, flip angle = 9°, and field of view (FOV) = 256 mm. This yielded 176 contiguous 1 mm thick slices in a sagittal orientation.